Compare · CMPI vs KVUE
CMPI vs KVUE
Side-by-side comparison of Checkmate Pharmaceuticals Inc. (CMPI) and Kenvue Inc. (KVUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- CMPI operates in Consumer Durables, while KVUE operates in Consumer Discretionary - the two are in different parts of the market.
- KVUE is the larger of the two at $34.00B, about 717.8x CMPI ($47.4M).
- KVUE has hit the wire 14 times in the past 4 weeks while CMPI has been quiet.
- KVUE has more recent analyst coverage (25 ratings vs 1 for CMPI).
- Company
- Checkmate Pharmaceuticals Inc.
- Kenvue Inc.
- Price
- $10.49+0.00%
- $17.61-0.54%
- Market cap
- $47.4M
- $34.00B
- 1M return
- -
- -0.70%
- 1Y return
- -
- -17.26%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 2023
- News (4w)
- 0
- 14
- Recent ratings
- 1
- 25
Checkmate Pharmaceuticals Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest CMPI
- Axonis Therapeutics Announces $115 Million Series A Financing
- venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies
- SEC Form 15-12B filed by Checkmate Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D/A filed by Checkmate Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13D filed by Checkmate Pharmaceuticals Inc.
- SEC Form EFFECT filed by Checkmate Pharmaceuticals Inc.
- Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers $2.5M Milestone Payment to XOMA
- SEC Form 25-NSE filed by Checkmate Pharmaceuticals Inc.
Latest KVUE
- SEC Form SD filed by Kenvue Inc.
- SEC Form 4 filed by Director Smith Jeffrey C
- SEC Form 4 filed by Director Hofstetter Sarah
- SEC Form 4 filed by Director Holden Betsy D
- SEC Form 4 filed by Director Merlo Larry J
- SEC Form 4 filed by Director Sneed Michael E
- SEC Form 4 filed by Director Prabhu Vasant M
- Group President LATAM Curado Gomes De Lemos Leonardo converted options into 24,248 shares and covered exercise/tax liability with 7,141 shares (SEC Form 4)
- SEC Form 4 filed by Director Healey Melanie
- SEC Form 4 filed by Director Pawlus Kathleen M